Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huhuang Jiangtang is a botanical drug candidate, specifically a Traditional Chinese Medicine (TCM) formulation, developed by Beijing Shijia Jiushengyuan Pharmaceutical Technology for the treatment of type 2 diabetes mellitus. The drug is administered orally in capsule form. It has been evaluated in Phase 1 clinical trials in China (e.g., CTR20131793) to assess its safety, tolerability, and preliminary pharmacokinetic profiles in healthy volunteers. Like many TCM products, it is a multi-component mixture intended to regulate blood glucose levels through complex, multi-target interactions, although its specific molecular mechanism of action has not been definitively characterized in public clinical records.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huhuang Jiangtang.